Alexion Pharmaceuticals

Alexion Pharmaceuticals is an American biopharmaceutical company focused on therapies for rare and ultra-rare disorders. It is widely identified as the developer of Soliris (eculizumab), used to treat conditions including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [1]. The company has been part of AstraZeneca since its acquisition, which completed in 2021 [2].Logo Index preserves an archived mark associated with Alexion Pharmaceuticals. The sources cited here identify the company and its focus but do not document the logo’s designer, the date it was introduced, or its design rationale, so that information is not available in these sources.

Logo Index is an independent educational archive covering logos, visual identities and graphic design history. All trademarks and brand assets remain the property of their respective owners.